Research Article
BibTex RIS Cite

İdiopatik Parkinson Hastalığında Tiyol-disülfid Homeostazisi

Year 2020, Volume: 10 Issue: 1, 39 - 45, 01.04.2020

Aybala Neslihan Alagöz Nimet Uçaroğlu Can Hayrullah Yazar Sıdıka Sinem Taşdemir

Abstract

Amaç: İdiyopatik Parkinson Hastalığı (PH) santral sinir sisteminin belli bölgelerinde, ilerleyici nöron kaybı ile seyreden nörodejeneratif bir hastalıktır. Pek çok nörodejeneratif hastalığın etiyolojisinde rolü olan serbest radikallerinin etkilerini azaltmak ve oluşturdukları hasarları ortadan kaldırmak için; organizmalar, kompleks antioksidan sistemler geliştirmişlerdir. Parkinson Hastalığı’nda oksidatif stresin patofizyolojik bir rol oynadığı düşünülmektedir. Bu çalışmada, dinamik tiyol-disülfid homeostazisinin PH patofizyolojisinde bir oksidatif stres belirteci olarak oynadığı rolün ve hastalığın özellikleri ile ilişkisinin araştırılması hedeflenmiştir. Materyal ve Metot: Bu çalışma 36 PH ve 22 sağlıklı kontrol ile yapılmıştır. Serumda Total Tiyol (TT) (μmol/L) ve Native Tiyol (NT) (μmol/L) ölçümleri yapılarak, tiyollerin bütüncül ölçümleri yapılmış ve yeni bir oksidatif belirteç olan tiyol/disülfid dengesi tespit edilmiştir. Bulgular: NT düzeyleri hasta grubunda daha düşük bulundu (p<0,05). NT ve TT düzeyleri UPDRS skorları ile ve TT düzeyi H-Y evresi ile (-) ilişki içinde saptandı (p<0,05). Sonuç: Tiyol-disülfid homeostazisinin oksidatif süreç lehine bozulduğunu düşündüren bu bulgular ile PH patofizyolojisinde ve ilerleyişinde bu mekanizmanın önemi vurgulanabilir

Keywords

Parkinson hastalığı; tiyol; tiyol disülfid homeostazisi; oksidasyon; nörodejenerasyon

References

  • 1. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson’s disease. Science 2003;302:819–22.
  • 2. Litvan I, Chesselet MF, Gasser T, Di Monte DA, Parker D Jr, Hagg T, et al. The etiopathogenesis of Parkinson disease and suggestions for future research. Part II J Neuropathol Exp Neurol 2007;66:329–36.
  • 3. Rubino FA. Gait disorders: Recognition of classic types. In: Adler CH, Ahlskog JE, editors. Parkinson’s Disease and Movement Disorders: Diagnosis and Treatment Guideliness for the Practicing Physician. Totowa: Humana Press; 2000:411–25.
  • 4. Parkinson, J. An essay on the shaking palsy. J Neuropsychiatrry Clin Neurosci 2002;14(2):223–36.
  • 5. Diplock, A. Healty lifestyles nutrition and physical activity: Antioxidant nutrients. ILSI Europe Concise Monograph Series, 1998:59.
  • 6. Sen CK, Packer L. Thiol homeostasis and supplements in physical exercise. Am J Clin Nutr 2000;72:653–69.
  • 7. Gumusyayla S, Vural G, Bektas H, Deniz O, Neselioglu S, Erel O. A novel oxidative stress marker in patients with Alzheimer’s disease: dynamic thiol-disulphide homeostasis. Acta Neuropsychiatr 2016;28(6):315–20.
  • 8. Herdegen T. Neurobiologisghe Grundlagen der Funktion und degenerativen Storungen des Nervensystems. In: Herdegen T, et al. Klinische Neurobiologie. Spektrum Akademischer Verlag, Heilderberg, 1997:1–38.
  • 9. Erel O, Neselioglu S. A novel and automated assay for thiol/ disulphide homeostasis. Clin Biochem 2014;47(18):326–32.
  • 10. Turell L, Radi R, Alvarez B. The thiol pool in human plasma: the central contribution of albumin to redox processes. Free Radic Biol Med 2013;65:244–53.
  • 11. Zecca L, Zucca FA, Wilms H, Sulzer D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci 2003;26:578–80.
  • 12. Durrieu G, Lau MEL, Rascol O, Senard JM, Rascol A, Montastruc JL. Parkinson’s disease and weight loss: a study with anthropometric and nutritional assessment. Clin. Auton. Res 1992;2:153–57.
  • 13. Vural G, Gumusyayla S, Bektas H, Deniz O, Alisik M, Erel O. Impairment of dynamic thiol-disulphide homeostasis in patients with idiopathic Parkinson’s disease and its relationship with clinical stage of disease. Clin Neurol Neurosorg 2017;153:50–55.
  • 14. Fedorow H, Tribl F, Halliday G, Gerlach M, Riederer P, Double KL. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson’s disease. Prog. Neurobiol 2005;75:109–24.
  • 15. Double KL, Ben-Shachar D, Youdim MBH, Zecca L, Riederer P, Gerlach M. Influence of neuromelanin on oxidative pathways within the human substantia nigra. Neurotoxicol. Teratol 2002;24:621–28.
  • 16. Cotzias GC, Miller ST, Tang LC, Papavasililiou PS. Levodopa, fertility, and longevity. Science 1977;196:549–51.
  • 17. Mena MA, Davila V, Sulzer D. Neurotrophic effects of L-dopa in postnatal midbrain dopamine/cortical astrocyte cocultures. J. Neurochem 1997;69:1398–1408.
  • 18. Kırbas A, Kırbas S, Cure MC, Tufekci A. Paraoxonase and arylesterase activity and total oxidative/anti-oxidative status in patients with idiopathic Parkinson’s disease. J. Clin. Neurosci 2014;21:451–55.

Year 2020, Volume: 10 Issue: 1, 39 - 45, 01.04.2020

Aybala Neslihan Alagöz Nimet Uçaroğlu Can Hayrullah Yazar Sıdıka Sinem Taşdemir

Abstract

References

  • 1. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson’s disease. Science 2003;302:819–22.
  • 2. Litvan I, Chesselet MF, Gasser T, Di Monte DA, Parker D Jr, Hagg T, et al. The etiopathogenesis of Parkinson disease and suggestions for future research. Part II J Neuropathol Exp Neurol 2007;66:329–36.
  • 3. Rubino FA. Gait disorders: Recognition of classic types. In: Adler CH, Ahlskog JE, editors. Parkinson’s Disease and Movement Disorders: Diagnosis and Treatment Guideliness for the Practicing Physician. Totowa: Humana Press; 2000:411–25.
  • 4. Parkinson, J. An essay on the shaking palsy. J Neuropsychiatrry Clin Neurosci 2002;14(2):223–36.
  • 5. Diplock, A. Healty lifestyles nutrition and physical activity: Antioxidant nutrients. ILSI Europe Concise Monograph Series, 1998:59.
  • 6. Sen CK, Packer L. Thiol homeostasis and supplements in physical exercise. Am J Clin Nutr 2000;72:653–69.
  • 7. Gumusyayla S, Vural G, Bektas H, Deniz O, Neselioglu S, Erel O. A novel oxidative stress marker in patients with Alzheimer’s disease: dynamic thiol-disulphide homeostasis. Acta Neuropsychiatr 2016;28(6):315–20.
  • 8. Herdegen T. Neurobiologisghe Grundlagen der Funktion und degenerativen Storungen des Nervensystems. In: Herdegen T, et al. Klinische Neurobiologie. Spektrum Akademischer Verlag, Heilderberg, 1997:1–38.
  • 9. Erel O, Neselioglu S. A novel and automated assay for thiol/ disulphide homeostasis. Clin Biochem 2014;47(18):326–32.
  • 10. Turell L, Radi R, Alvarez B. The thiol pool in human plasma: the central contribution of albumin to redox processes. Free Radic Biol Med 2013;65:244–53.
  • 11. Zecca L, Zucca FA, Wilms H, Sulzer D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci 2003;26:578–80.
  • 12. Durrieu G, Lau MEL, Rascol O, Senard JM, Rascol A, Montastruc JL. Parkinson’s disease and weight loss: a study with anthropometric and nutritional assessment. Clin. Auton. Res 1992;2:153–57.
  • 13. Vural G, Gumusyayla S, Bektas H, Deniz O, Alisik M, Erel O. Impairment of dynamic thiol-disulphide homeostasis in patients with idiopathic Parkinson’s disease and its relationship with clinical stage of disease. Clin Neurol Neurosorg 2017;153:50–55.
  • 14. Fedorow H, Tribl F, Halliday G, Gerlach M, Riederer P, Double KL. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson’s disease. Prog. Neurobiol 2005;75:109–24.
  • 15. Double KL, Ben-Shachar D, Youdim MBH, Zecca L, Riederer P, Gerlach M. Influence of neuromelanin on oxidative pathways within the human substantia nigra. Neurotoxicol. Teratol 2002;24:621–28.
  • 16. Cotzias GC, Miller ST, Tang LC, Papavasililiou PS. Levodopa, fertility, and longevity. Science 1977;196:549–51.
  • 17. Mena MA, Davila V, Sulzer D. Neurotrophic effects of L-dopa in postnatal midbrain dopamine/cortical astrocyte cocultures. J. Neurochem 1997;69:1398–1408.
  • 18. Kırbas A, Kırbas S, Cure MC, Tufekci A. Paraoxonase and arylesterase activity and total oxidative/anti-oxidative status in patients with idiopathic Parkinson’s disease. J. Clin. Neurosci 2014;21:451–55.
There are 18 citations in total.

Details

Primary Language Turkish
Subjects Clinical Sciences
Journal Section Research Article
Authors

Aybala Neslihan Alagöz This is me

Nimet Uçaroğlu Can This is me

Hayrullah Yazar This is me

Sıdıka Sinem Taşdemir This is me

Publication Date April 1, 2020
Published in Issue Year 2020 Volume: 10 Issue: 1

Cite

APA Alagöz, A. N., Can, N. U., Yazar, H., Taşdemir, S. S. (2020). İdiopatik Parkinson Hastalığında Tiyol-disülfid Homeostazisi. Kafkas Journal of Medical Sciences, 10(1), 39-45.
AMA Alagöz AN, Can NU, Yazar H, Taşdemir SS. İdiopatik Parkinson Hastalığında Tiyol-disülfid Homeostazisi. KAFKAS TIP BİL DERG. April 2020;10(1):39-45.
Chicago Alagöz, Aybala Neslihan, Nimet Uçaroğlu Can, Hayrullah Yazar, and Sıdıka Sinem Taşdemir. “İdiopatik Parkinson Hastalığında Tiyol-disülfid Homeostazisi”. Kafkas Journal of Medical Sciences 10, no. 1 (April 2020): 39-45.
EndNote Alagöz AN, Can NU, Yazar H, Taşdemir SS (April 1, 2020) İdiopatik Parkinson Hastalığında Tiyol-disülfid Homeostazisi. Kafkas Journal of Medical Sciences 10 1 39–45.
IEEE A. N. Alagöz, N. U. Can, H. Yazar, and S. S. Taşdemir, “İdiopatik Parkinson Hastalığında Tiyol-disülfid Homeostazisi”, KAFKAS TIP BİL DERG, vol. 10, no. 1, pp. 39–45, 2020.
ISNAD Alagöz, Aybala Neslihan et al. “İdiopatik Parkinson Hastalığında Tiyol-disülfid Homeostazisi”. Kafkas Journal of Medical Sciences 10/1 (April 2020), 39-45.
JAMA Alagöz AN, Can NU, Yazar H, Taşdemir SS. İdiopatik Parkinson Hastalığında Tiyol-disülfid Homeostazisi. KAFKAS TIP BİL DERG. 2020;10:39–45.
MLA Alagöz, Aybala Neslihan et al. “İdiopatik Parkinson Hastalığında Tiyol-disülfid Homeostazisi”. Kafkas Journal of Medical Sciences, vol. 10, no. 1, 2020, pp. 39-45.
Vancouver Alagöz AN, Can NU, Yazar H, Taşdemir SS. İdiopatik Parkinson Hastalığında Tiyol-disülfid Homeostazisi. KAFKAS TIP BİL DERG. 2020;10(1):39-45.
 Download Cover Image